
Atea Pharmaceuticals (AVIR) Stock
Clinical stage biotech developing oral antiviral drugs for viruses. Here's the price, business snapshot, and what's worth knowing about Atea Pharmaceuticals in November 2026.
Atea Pharmaceuticals Inc (ticker AVIR) is a clinical-stage biopharmaceutical company focussed on developing oral antiviral therapies targeting RNA viruses. With a market capitalisation of about $261.09 million, Atea operates at the development end of the biotech spectrum: value drivers include clinical trial results, regulatory decisions, partnership or licensing deals, and potential commercial prospects. As a clinical-stage company it typically generates limited product revenue and relies on financing, collaborations and milestone payments to fund research and operations. Shares can be volatile around trial readouts and regulatory news. Key risks include clinical failure, regulatory rejection, competitive pressure and potential dilution from future fundraising. This summary is educational and not personalised advice; investors should consider their risk tolerance, review company filings, and may wish to consult a regulated financial adviser. Small-cap biotech investments are generally more suitable for those who can accept high volatility and the possibility of losing their capital.
Atea Pharmaceuticals (AVIR) Stock Forecast
Analyst price target, next 12 months
$6.67
+58.7% vs today's $4.20
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Atea Pharmaceuticals have a consensus 12-month target of $6.67, above the current price of $4.20.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 20 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Atea Pharmaceuticals' stock, anticipating a price increase to $6.67.
Financial Health
ATEA Pharmaceuticals is showing strong cash generation and solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Progress & Trials
Clinical trial outcomes and regulatory updates are primary value drivers; positive readouts can boost interest, while negative news can cause sharp declines.
Drug Development Focus
The company focuses on oral antivirals with potential broad application, but development is lengthy and subject to regulatory scrutiny and competition.
Market Dynamics and Risks
A relatively small market capitalisation implies higher volatility and funding dependence; investors should weigh the upside against the risk of dilution and trial setbacks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.